Please login to the form below

Not currently logged in

paliperidone palmitate

This page shows the latest paliperidone palmitate news and features for those working in and with pharma, biotech and healthcare.

J&J gets quicker review for schizophrenia depot in US

J&J gets quicker review for schizophrenia depot in US

The US FDA has granted priority review status to Johnson &Johnson's paliperidone palmitate depot, which if approved will become the first schizophrenia drug that can be administered just four times ... The current formulation of paliperidone - sold as

Latest news

  • Double win for J&J's schizophrenia franchise Double win for J&J's schizophrenia franchise

    Added to that, the pharma company has just stopped a trial of its three-monthly formulation of Risperdal (risperidone) follow-up paliperidone palmitate on positive results, setting up a filing later ... Three-monthly paliperidone. Meanwhile, J&J could

  • OTC recovery helps J&J in first-quarter OTC recovery helps J&J in first-quarter

    The company said the sales increase was also helped by new pharmaceutical product introductions, including its depot antipsychotic Invega Sustenna/Xeplion (paliperidone palmitate), which grew 76 per cent to $284m in

  • Prix Galien shortlist announced

    Janssen-Cilag's nominations in the Innovative Product category are Xeplion (paliperidone palmitate) for schizophrenia, prostate cancer drug Zytiga (abiraterone acetate) and Incivo (telaprevir).

  • J&J sales up 8.3 per cent

    Behind this growth were recent product launches and approvals, including psoriasis treatment Stelara (ustekinumab); prostate cancer drug Zytiga (abiraterone acetate) and Invega Sustenna (paliperidone palmitate) for schizophrenia.

  • Alkermes to buy Elan unit

    Cooke also commented on the deal, reference the company's future product prospects: "With EDT's two recently approved drugs, Invega Sustenna (paliperidone palmitate – for schizophrenia) and Ampyra (dalfampridine – for multiple

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...